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hoOBJECTIVES This study sought to evaluate the effects of the Carillon device on mitral regurgitation severity and left
ventricular remodeling.
BACKGROUND Functional mitral regurgitation (FMR) complicates heart failure with reduced ejection fraction and is
associated with a poor prognosis.
METHODS In this blinded, randomized, proof-of-concept, sham-controlled trial, 120 patients receiving optimal heart
failure medical therapy were assigned to a coronary sinus-based mitral annular reduction approach for FMR or sham. The
pre-speciﬁed primary endpoint was change in mitral regurgitant volume at 12 months, measured by quantitative
echocardiography according to an intention-to-treat analysis.
RESULTS Patients (69.8  9.5 years of age) were randomized to either the treatment (n ¼ 87) or the sham-controlled
(n ¼ 33) arm. There were no signiﬁcant differences in baseline characteristics between the groups. In the treatment
group, 73 of 87 (84%) had the device implanted. The primary endpoint was met, with a statistically signiﬁcant reduction
in mitral regurgitant volume in the treatment group compared to the control group (decrease of 7.1 ml/beat [95%
conﬁdence interval [CI]: 11.7 to 2.5] vs. an increase of 3.3 ml/beat [95% CI: 6.0 to 12.6], respectively; p ¼ 0.049).
Additionally, there was a signiﬁcant reduction in left ventricular volumes in patients receiving the device versus those in
the control group (left ventricular end-diastolic volume decrease of 10.4 ml [95% CI: 18.5 to 2.4] vs. an increase of
6.5 ml [95% CI: 5.1 to 18.2]; p ¼ 0.03 and left ventricular end-systolic volume decrease of 6.2 ml [95% CI: 12.8 to
0.4] vs. an increase of 6.1 ml [95% CI: 1.42 to 13.6]; p ¼ 0.04).
CONCLUSIONS The Carillon device signiﬁcantly reduced mitral regurgitant volume and left ventricular volumes
in symptomatic patients with functional mitral regurgitation receiving optimal medical therapy. (Carillon
Mitral Contour System for Reducing Functional Mitral Regurgitation [REDUCE FMR]; NCT02325830)
(J Am Coll Cardiol HF 2019;7:945–55) © 2019 The Authors. Published by Elsevier on behalf of the American College of
Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
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946C hronic heart failure is common,occurring in 1% to 2% of adults indeveloped countries and $10% of
those 70 years of age or older (1). Functional
(or secondary) mitral regurgitation (FMR) is a
frequent ﬁnding in patients with heart fail-
ure (2). Patients with FMR and heart failure
with reduced ejection fraction (HFrEF) have
worse morbidity and mortality than patients
with HFrEF without FMR, even when the
mitral regurgitation is mild (2–4). Therefore,
strategies which reduce FMR may have a
favorable impact on clinical outcomes. This
hypothesis was supported by a recent trial
which demonstrated an improvement in
clinical outcomes in patients with moderate
to severe FMR treated with a percutaneous
leaﬂet clipping device (5).The Carillon mitral contour system (Cardiac Di-
mensions, Kirkland, Washington), a mitral annulo-
plasty device delivered percutaneously to the
coronary sinus (Central Illustration), is designed to
reduce the mitral annular dimension by virtue of the
close anatomic relationship between the coronary
sinus and the posterior mitral annulus. Single-arm
observational core laboratory-adjudicated studies
have shown that this approach reduces mitral regur-
gitation and improves exercise capacity and symp-
toms and quality of life in patients with HFrEF and
FMR (6–8). These studies have also provided evi-
dence of left ventricular (LV) reverse remodeling.
The REDUCE-FMR (Carillon Mitral Contour System
for Reducing Functional Mitral Regurgitation) study
was the ﬁrst sham-controlled randomized trial of any
catheter-based therapy for patients with valvular heart
disease. The aim was to evaluate the effects of the
Carillon device on FMR severity and LV remodeling.SEE PAGE 956METHODS
STUDY DESIGN. The REDUCE-FMR trial was a
double-blinded, multicenter, randomized, proof-of-
concept, sham-controlled trial of the Carillon mitral
contour system. The study design has been reporteds stock in Cardiac Dimensions. Dr. Sievert has received grants from
ancial support from 4tech Cardio, Abbott, Ablative Solutions, A
Boston Scientiﬁc, Carag, Celonova, Comed BV, Contego, CVRx,
edtech, Lifetech, Maquet Getinge Group, Medtronic, Mitralign, M
l, Terumo, Vascular Dynamics, Vectorious Medtech, Venus, and V
o relationships relevant to the contents of this paper to disclose
received May 15, 2019; revised manuscript received June 12, 201previously (9). The trial was approved by the insti-
tutional review board or local Competent Authority/
Ethics Committee at each participating site, and pa-
tients provided written informed consent.
STUDY PATIENTS. Eligibility requirements at
screening included an age of at least 18 years, symp-
toms of New York Heart Association (NYHA) func-
tional class II, III, or IV, an LV ejection fraction (LVEF)
of <50%, an LV end-diastolic diameter more than
55 mm, and an FMR grade of 2þ, 3þ, or 4þ, despite
the use of stable ($3-month) guideline-directed
medical therapy. In addition, patients had to have
the ability to complete a 6-min walk distance of
150 to 450 m to conﬁrm exercise limitation while
proving capacity for serial 6-min walk testing.
Key exclusion criteria included percutaneous cor-
onary intervention in the previous 30 days, prior mitral
valve surgery, signiﬁcant organic mitral valve pathology,
severe mitral annular calciﬁcation, and existing or indi-
cation for cardiac resynchronization therapy.
STUDY PROCEDURES. After undergoing screening
for clinical eligibility, patients provided informed
written consent. They then underwent quantitative
transthoracic echocardiography by appropriately
trained local echocardiographers for the assessment
of mitral regurgitation and LV structure and function.
After review by the local investigator, with the sup-
port of the local heart valve multidisciplinary team
according to local practice, a decision was made about
the patient’s suitability for mitral valve intervention
and speciﬁcally for the REDUCE-FMR study.
At a subsequent study visit, patients underwent a
6-min walk test, submitted blood tests for renal
function and natriuretic peptides, and completed
a Kansas City Cardiomyopathy Quality of Life
Questionnaire (KCCQ). (10)
Following this, patients were taken to the cardiac
catheterization laboratory, where they were put un-
der either general anesthesia (n ¼ 47) or conscious
sedation, using headphones and blindfolds (n ¼ 73) as
required to maintain blinding. Patients underwent
coronary angiography through radial or femoral
access. A 10-F sheath was inserted into the right in-
ternal jugular vein, and a Carillon delivery catheter
was used to engage the coronary sinus. QuantitativeCardiac Dimensions; and has received grants, fees,
ncora Heart, Bavaria Medizin Technologie GmbH,
Dinova, Edwards, Endologix, Hemoteq, Hangzhou
okita, Occlutech, pfm Medical, Recor, Renal Guard,
ivasure Medical. All other authors have reported that
.
9, accepted June 17, 2019.
CENTRAL ILLUSTRATION The REDUCE-FMR Trial
REDUCE-FMR
A Randomized, Double-Blind, Proof-of-Concept Study of the Carillon
Device in 120 Patients with HFrEF and FMR Showing:
Mitral regurgitant volume
Left ventricular end-diastolic
volume
Left ventricular end-systolic
volumeMitral annulus remodeled with
Carillon device
Mitral annulus dilation before
implantation of Carillon device
12 months
Witte, K.K. et al. J Am Coll Cardiol HF. 2019;7(11):945–55.
The REDUCE-FMR (Carillon Mitral Contour System for Reducing Functional Mitral Regurgitation) trial was a randomized, placebo-controlled, double-
blind, proof-of-concept study that demonstrated signiﬁcant reductions in mitral regurgitation as well as reverse remodeling at 1 year in a comparison
between the Carillon mitral contour system and a sham procedure.
J A C C : H E A R T F A I L U R E V O L . 7 , N O . 1 1 , 2 0 1 9 Witte et al.
N O V E M B E R 2 0 1 9 : 9 4 5 – 5 5 Percutaneous Repair of FMR
947venous angiography was performed. If the venous
dimensions were suitable in diameter and length for a
Carillon device, randomization was performed. In
patients randomized to sham control, the procedure
was terminated and the sheaths withdrawn. In pa-
tients randomized to device implantation, an appro-
priately sized device was inserted into the delivery
catheter and deployed (Central Illustration). The distal
anchor was unsheathed and locked in a suitable
segment of the great cardiac vein. Tension was
applied, and the proximal anchor was deployed in the
desired location if left coronary angiography had
conﬁrmed no impingement of or obstruction to ﬂow
in the circumﬂex coronary artery or its branches.
Subsequently, patients underwent echocardiographic
and clinical follow-up at 1, 6, and 12 months after the
procedure. All echocardiograms were interpreted ac-
cording to established guidelines (11,12). Speciﬁcally,
in the assessment of mitral regurgitation, a multi-
parametric and quantitative approach was used todivide FMR into 4 grades (12) (see the Online
Appendix for trial deﬁnitions of FMR).
RANDOMIZATION AND MASKING. Randomization
was performed through a Web portal, in a device-to-
control ratio of 3:1. A 3:1 ratio was chosen to
improve recruitment and to provide more data for
patients carrying implanted devices with a view to
post hoc mechanistic work (9). Randomization was
stratiﬁed according to investigation center in a ran-
domized permuted blocks design. The study statisti-
cian generated the randomization schedule
(independent of the sponsor). Clinical assessors and
the core echocardiographic laboratory (Cleveland
Clinic) were blinded to the patient’s allocation and
follow-up time points. Speciﬁcally, echocardiograms
were not read sequentially, and all patients under-
went standard echocardiograms at baseline and dur-
ing follow-up, including those not implanted with a
device. Although occasionally the device was visible
FIGURE 1 CONSORT Flow Diagram
Patient disposition during the trial. CONSORT ¼ Consolidated Standards of Reporting Trials.
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948on transesophageal echocardiograms, only trans-
thoracic echocardiogram images were used for data
analysis. Care was taken to avoid documentation in
the medical records as to whether the patients
received a device. Patients were questioned after the
procedure at discharge and at each visit as to whether
they thought they received a device or not, to assess
for effectiveness of blinding.
STUDY OUTCOMES. The pre-speciﬁed primary
endpoint was a comparison of changes in mitralregurgitant volumes at 1 year compared with baseline,
between the treatment group and the sham control
group, as assessed by the independent, blinded
echocardiographic core laboratory using quantitative
echocardiography. Secondary safety endpoints were
major adverse events (MAEs), deﬁned as death,
myocardial infarction, device embolization, vessel
erosion, cardiac perforation, need for cardiac surgery
or percutaneous coronary intervention associated
with device failure, and heart failure hospitalizations.
TABLE 1 Characteristics of Randomized Patients at Baseline According to ITT Analysis
Total (N ¼ 120) Control (n ¼ 33) Treatment (n ¼ 87)
Men 87 (72.5) 24 (72.7) 63 (72.4)
Mean age, yrs 69.8  9.5 69.1  8.9 70.1  9.7
Cause
Ischemic heart disease 80 (66.7) 21 (63.6) 59 (67.8)
Nonischemic cardiomyopathy 40 (33.3) 12 (36.4) 28 (32.2)
Diabetes mellitus 36 (30.0) 12 (36.4) 24 (27.6)
BMI, kg/m2 27.1  5.6 28.1  6.2 26.7  5.3
NYHA functional class
II 55 (45.8) 16 (48.5) 39 (44.8)
III 63 (52.5) 17 (51.5) 46 (52.9)
IV 2 (1.7) 0 (0.0) 2 (2.3)
Beta blockers 109 (90.8) 32 (97.0) 77 (88.5)
ACE inhibitor/ARB/ARNi 108 (90.0) 29 (87.9) 79 (90.8)
Diuretic agent 118 (98.3) 33 (100) 85 (97.7)
MRA diuretic agent 73 (60.8) 19 (57.6) 54 (62.1)
NT-pro-BNP 2,430
(1,092–4,440)
2,410
(1,151–4,820)
2,505
(1,095–4,386)
Device (ICD or PPM) 55 (45.8) 12 (36.4) 43 (49.4)
Atrial ﬁbrillation 71 (59.2) 20 (60.6) 51 (58.6)
Baseline heart rate, beats/min 70  12 70  11 70  13
Systolic BP, mm Hg 119  17 119  19 118  16
Diastolic BP, mm Hg 70  11 67  13 71  11
6-min walk test 302.6  90.6 292.6  91.5 306.4  90.5
LVEF, % 34  9 37  9 34  9
LVEDD, cm 6.4  0.9 6.4  0.9 6.4  0.9
LVESD, cm 5.5  1.0 5.3  1.1 5.5  1.0
LVEDV, ml 187.4  67.9 188.6  75.7 187.0  65.6
LVESV, ml 126.1  56.8 122.0  59.8 127.4  56.1
Mitral regurgitant volume, ml/beat 39.9  23.8 38.1  24.0 40.4  23.9
Mitral regurgitant grade
1þ 35 (29.7) 10 (32.3) 25 (28.7)
2þ 42 (35.6) 8 (25.8) 34 (39.1)
3þ 34 (28.8) 11 (35.5) 23 (26.4)
4þ 7 (5.9) 2 (6.5) 5 (5.7)
Mean creatinine, mmol/l 114.1  31.9 118.8  34.1 112.3  31.1
Values are n (%), mean  SD, or median (interquartile range). There were no signiﬁcant differences between the
groups on appropriate post hoc testing. Conversion factors: creatinine mmol/l  0.011 ¼ mg/dl.
ACE ¼ angiotensin-converting enzyme inhibitor; ARB ¼ aldosterone receptor blocker; ARNi ¼ angiotensin
receptor-neprilysin inhibitor; BMI ¼ body mass index; BP ¼ blood pressure; ICD ¼ implantable cardioverter-
deﬁbrillator; ITT ¼ intention to treat; LVEDD ¼ left ventricular end-diastolic diameter; LVEDV ¼ left ventricu-
lar end-diastolic volume; LVEF ¼ left ventricular ejection fraction; LVESD ¼ left ventricular end-systolic diameter;
LVESV ¼ left ventricular end-systolic volume; MRA ¼ mineralocorticoid receptor antagonists; NT-pro-
BNP ¼ N-terminal pro–B-type natriuretic peptide; NYHA ¼ New York Heart Association; PPM ¼ permanent
pacemaker.
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949Secondary efﬁcacy endpoints were changes in LV end-
diastolic and end-systolic volumes, changes in 6-min
walk distances, NYHA functional class, and quality
of life at 12 months compared to baseline. A 5-point
change in KCCQ score was considered clinically
signiﬁcant (13).
STATISTICAL ANALYSIS. The minimum required
sample size was calculated as 76 randomized pa-
tients. This assumed a reduction in mitral regurgitant
volume of 12.4 ml/beat and 2.4 ml/beat in treatment
and control groups, respectively, with an assumed
SD of 13 ml/beat. It was predicted that a loss to
follow-up of 30% would give 80% power to identify
this difference with a 0.05 alpha value. Analyses were
performed and are presented according to intent-to-
treat with subjects analyzed according to the ran-
domized assignment regardless of actual treatment
received, unless otherwise speciﬁed.
The primary efﬁcacy endpoint of change in mitral
regurgitant volumewas calculated as themean change
between groups among subjects with evaluable
data. Between-group comparisons were performed
using Student’s t-test. Binomial proportions were
compared between treatment groups using Fisher
exact test, whereas within-arm differences in binomial
proportions between baseline and 12 months were
tested usingMcNemar’s test. Wilcoxon’s rank sum test
was used to compare ordinal outcomes such as
changes in NYHA functional class between groups,
whereas theWilcoxon signed rank test was used to test
for a statistically signiﬁcant change within each
treatment arm. Additional outcomes are presented as
mean change from baseline for continuous variables
and number and frequency for categorical variables.
The study was not powered to assess differences in
clinical outcomes. Post hoc analyses were conducted
of patients with severe FMR (grade$3þ) at baseline. A
2-sided p value of <0.05 was considered signiﬁcant in
all analyses. Statistical analysis was performed with
SAS version 9.4 software (SAS Institute, Cary, North
Carolina).
RESULTS
Between March 2015 and July 2017, 163 patients
consented to undergo detailed baseline screening, of
whom 135 patients were enrolled at 24 centers in
Europe and Australia. Of these patients, 15 patients
were excluded before randomization because they
did not meet inclusion criteria (n ¼ 8), there was
failure to adequately engage the coronary sinus
(n ¼ 2), or there was guidewire vein dissection (n ¼ 5).
Therefore, 120 patients were randomized, 87 to
treatment and 33 to sham control (Figure 1). In 14 ofthose allocated to treatment (16%) no device was
implanted due most commonly to coronary
impingement (n ¼ 8), which resolved in all instances
following device removal. Other reasons included
coronary venous dissection (n ¼ 2), failure of the
distal anchor to maintain tension (n ¼ 2), and clinical
site logistical issues (n ¼ 2: no correct size device
available and misunderstanding of the outcome of
randomization at site level).
STUDY PATIENTS. Patient characteristics are listed in
Table 1. The cohorts were well matched with regard to
key inclusion and clinical severity. Patients were
TABLE 2 Primary and Secondary Outcomes According to ITT Analysis
Endpoint
Randomized
Treatment
Mean Change (95% CI)
or Median (Interquartile Range)
After 12 Months
Difference in Mean Change
or Estimate (95% CI) p Value
Primary outcome
Mitral regurgitant volume, ml/beat Control (n ¼ 13) 3.32 (5.98, 12.62) 10.39 (0.06, 20.71) 0.049
Treatment (n ¼ 55) 7.07 (11.68, 2.46)
Secondary outcomes: LV parameters
LVEDV, ml Control (n ¼ 16) 6.54 (5.14, 18.22) 16.96 (1.81, 32.12) 0.03
Treatment (n ¼ 47) 10.42 (18.48, 2.37)
LVESV, ml Control (n ¼ 16) 6.10 (1.42, 13.63) 12.29 (0.32, 24.28) 0.04
Treatment (n ¼ 47) 6.19 (12.78, 0.39)
LVEF, % Control (n ¼ 16) 0.40 (3.15, 2.36) 0.59 (4.11, 2.93) 0.74
Treatment (n ¼ 47) 0.19 (1.67, 2.06)
Secondary outcomes: patient-oriented
6-min walk distance, m* Control (n ¼ 20) 17.5 (20.0, 46.5) 14.5 (46.0, 20.0) 0.37
Treatment (n ¼ 65) 32.0 (10.0, 70.0)
KCCQ score Control (n ¼ 24) 7.63 (0.22, 15.05) 1.86 (11.36, 7.65) 0.70
Treatment (n ¼ 70) 9.49 (3.26, 15.71)
*Median measurement with interquartile range (Hodges-Lehmann location shift) and 95% CI due to non-normality of data
CI ¼ conﬁdence interval; KCCQ ¼ Kansas City Cardiomyopathy Quality of Life Questionnaire; other abbreviations as in Table 1.
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950taking optimally tolerated doses of guideline-directed
therapy, including beta-blockers, renin-angiotensin-
aldosterone system blockers, and loop diuretics.
Although echocardiographic evaluation was per-
formed at the site prior to enrolment, 35 patients
(29.7%) were later judged by the echocardiography
core laboratory to have had <2þ FMR at baseline.
EFFECTIVENESS OF BLINDING. In 285 of 298 patient
visits (96.5%), patients indicated that they felt un-
certain about their treatment assignment. Overall,
97.5% of control patients, 96.9% of nonimplanted,
treatment group patients, and 94.6% of implanted
patients indicated that they remained blinded
throughout the study. The echocardiographic core
laboratory indicated that they remained blinded.
Although the artifact of the Carillon device can oc-
casionally be seen on echocardiography, this can be
mimicked by mitral annular calciﬁcation, or other
artifacts in patients without Carillon devices. All
scans were anonymized with regard to patient iden-
tiﬁers and date and were analyzed in random order
after completion of follow-up, which contributed to
the effectiveness of the blinding.
PROCEDURAL AND SAFETY OUTCOMES. There were
no instances of device embolization or fractures,
cardiac perforations, or intraprocedural ischemic
events. Device implant time averaged 64.2  34.8 min
and total procedure times averaged 102.7  54.9 min.
Procedure time in the control group averaged
62.7  29.4 min. There were 2 deaths within 30 days,
both in implanted patients, due to progressive car-
diorenal deterioration. One of these events, in whichthe patient experienced a general deterioration due
to heart failure after the procedure was judged by the
Clinical Endpoints Committee as “possibly” related to
the procedure itself. Both of these patients had pre-
viously occluded circumﬂex arteries, and neither had
apparent coronary artery compression.
There were 3 myocardial infarctions in the device
group within 30 days (deﬁned by electrocardiogram
changes or coronary ﬂow limitation and troponin rise
to 5 the upper limit of normal). Only 1 of these
infarctions was associated with coronary artery
compression of an AV groove branch of the circumﬂex
coronary artery. This patient developed small Q
waves in leads I and aVL but completed 12-months of
follow-up with no further events or hospitalizations.
There were no new Q-waves or changes in EF in either
of the other 2 patients. There were no late myocardial
infarctions or other device-related deaths in implan-
ted patients. A control patient also experienced a late
myocardial infarction during the follow-up period,
which was adjudicated as not related to their
(sham) procedure. A table of all serious adverse
events over 12 months is included in the appendix
(Online Table 1).
PRIMARY ENDPOINT: MITRAL REGURGITATION. At
12 months, there was a 10.4 ml/beat (95% conﬁdence
interval [CI]: 0.1 to 20.7) difference in mean
mitral regurgitant volume between the 2 groups
(7.1 ml/beat [95% CI: 11.7 to 2.5] vs. 3.3 ml/beat
[95% CI: 5.98 to 12.62]; p ¼ 0.049) (Table 2). This
represented a median 22.4% decrease in mitral
regurgitant volume in the treatment group and a
FIGURE 2 Primary Endpoint: Mitral Regurgitant Volume
(A) Mean change in regurgitant volume at 12 months from paired data (7.1 ml/beat vs.
3.3 ml/beat; p ¼ 0.049). (B) Mean mitral regurgitation data at each time point
(unpaired data).
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951median 1.5% increase in mitral regurgitant volume in
the control arm (Figures 2A and 2B). Sensitivity anal-
ysis using imputation for unmeasurable values (as
determined by the independent core laboratory) and
last observation carry forward for missing data at
12 months conﬁrmed the primary analysis (p ¼ 0.03).
Paired echocardiography data of sufﬁcient quality
to allow for quantitative assessment of mitral regur-
gitation severity, as evaluated independently by the
echocardiographic core laboratory, were available in
68 patients (57%) (control patients: n ¼ 13 [39%]; pa-
tients who received implants: 45 [62%]; patients who
did not receive implants: 10 [71%]). Reasons for missed
1-year echocardiography studies included death (n ¼
16 deaths), insufﬁcient echocardiographic quality to
quantitate regurgitant volume (n ¼ 18), and regur-
gitant volume below the lower quantiﬁcation limit
(n ¼ 8). Echocardiographs were deemed “unreadable”
if there was insufﬁcient ability to obtain a quality
proximal isovelocity surface area measurement to
allow for regurgitant volume assessment. There were
no signiﬁcant differences in baseline variables be-
tween those patients with and those without paired
echocardiography data. Baseline characteristics of
patients who contributed to the primary endpoint
analysis were similar to the overall baseline subject
characteristics in regard to regurgitant volume,
ischemic cause, NYHA functional class, left ventricular
volume and diameter, and mitral regurgitation grade.
The post hoc analysis of changes in mean mitral
regurgitant volume, including only patients with se-
vere FMR (mitral regurgitation grade $3þ) at baseline
as determined by the core laboratory assessment,
was limited by patient numbers (n ¼ 15 in the treat-
ment arm and n ¼ 8 in the control arm), but revealed
a similar pattern of change (12.8 ml/beat
[95% CI: 24.7 to 0.8] vs. 0.6 ml/beat [95% CI: 13.0
to 14.2]; p ¼ 0.14) (Online Table 2). A further post hoc
as-treated analysis revealing similar outcomes is
shown in Online Tables 3 and 4.
The proportion of patients judged to have an
improvement in grade of FMR at 1 year was higher in
patients allocated to treatment than in those allo-
cated to control (50.0% vs. 20.0%, respectively;
p ¼ 0.02) (Figure 3). In patients with more severe FMR
(mitral regurgitation grade $3þ) at baseline (n ¼ 44),
the treatment effect was greater, with more implan-
ted patients judged to have had at least 1 grade
improvement in FMR at 1 year compared with control
patients (63% [10 of 16] vs. 10% [1 of 10], respectively;
p ¼ 0.01).
SECONDARY ENDPOINTS. There was evidence of
reverse remodeling with a signiﬁcant decrease in LV
end-diastolic volume (LVEDV) at 1 year in patientsallocated to treatment versus an increase in those
allocated to control (10.4 ml [95% CI: 18.5 to 2.4]
vs. 6.5 ml [95% CI: 5.1 to 18.2], respectively;
p ¼ 0.03). A similar effect was seen in end-systolic
volume (LVESV) at 1 year (6.2 ml [95% CI: 12.8 to
0.4] vs. 6.1 ml [95% CI: 1.4 to 13.6, respectively;
p ¼ 0.04) (Table 2, Figures 4A and 4B). These changes
in volumes between the 2 groups were greater in pa-
tients with more severe mitral regurgitation grades at
baseline ($3þ) (LVEDV: 26.9 ml [95% CI: 38.8
to 20.2] vs. 10.2 ml [95% CI: 16.2 to 34.3], respec-
tively; p < 0.001) (LVESV: 17.5 ml [95% CI: 28.9
to 6.1] vs. 7.0 ml [95% CI: 4.2 to 18.3], respectively;
p < 0.005). There were no overall differences in
changes in LVEF between the groups.
Table 2 shows the changes in 6-min walk test dis-
tances and KCCQ scores. Patients in the treatment
group had a signiﬁcant improvement in 6-min walk
FIGURE 4 Change
Volumes at 12 Mont
There was evidence
allocated to treatme
[95% CI: 18.5 to 2
seen in LVESV at 1 ye
p ¼ 0.04]). LVEDV ¼
end-systolic volume.
FIGURE 3 Change in Mitral Regurgitation Grade at 12 Months
At 12 months, a greater proportion of patients in the treatment
group experienced improvement in mitral regurgitation grade
than in the control group (p ¼ 0.02).
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952distances at 12 months compared with their baseline
distances (p ¼ 0.002), whereas patients allocated to
the control group did not (p ¼ 0.29). Figure 5 shows
symptoms assessed by the NYHA functional classiﬁ-
cation from baseline to follow-up in the 2 groups.
Patients in the treatment group had a signiﬁcant
improvement in NYHA functional class at 12 months
compared with their baseline measurements
(p ¼ 0.002), whereas patients allocated to the control
group did not (p ¼ 0.75). The REDUCE-FMR trial was
not powered for these clinical variables, and the
between-group analyses did not show signiﬁcance.
Patients who did not receive a device (including
controls and nonimplanted patients) were much morein Left Ventricular End Diastolic and Left Ventricular Systolic
hs
of reverse remodeling with a decrease LVEDV at 1 year in patients
nt versus an increase in those allocated to control (10.4 ml
.4] vs. 6.5 ml [95% CI: 5.1 to 18.2]; p ¼ 0.03). A similar effect was
ar (6.2 ml [95% CI: 12.8 to 0.4] vs. 6.1 ml [95% CI: 1.4 to 13.6;
left ventricular end-systolic diameter; LVESV ¼ left ventricularlikely to drop out of the study to receive another
device-based therapy or transplantation (12.8% [6 of
47] vs. 1.4% [1 of 73], respectively; p ¼ 0.01). The
incidence of MAEs was similar between groups
through the follow-up period (Table 3). There was a
nonsigniﬁcant difference in heart failure hospitali-
zation rate between the groups (0.57 [95% CI: 0.41 to
0.72] for treatment vs. 0.73 [95% CI: 0.44 to 1.03],
respectively, for control per patient year; p ¼ 0.34).
Patients allocated to the treatment group spent
approximately 1 month more alive and out of the
hospital than patients in the control group (319 vs.
291 days, respectively; p ¼ 0.33) and were one-half as
likely to have had multiple (>1) heart failure hospi-
talizations during follow-up (11% vs. 21%, respec-
tively; p ¼ 0.23).
DISCUSSION
REDUCE-FMR is the ﬁrst blinded, sham-controlled
study of a percutaneous device for valve therapy,
and the results should be put in the context that
many blinded sham-controlled trials in interventional
cardiology have shown neutral results (14–18). Pa-
tients randomly allocated to treatment with the
Carillon device experienced a signiﬁcant reduction in
mitral regurgitant volume at 12 months compared
with those allocated to the control arm. Importantly,
the implanted patients also had favorable LV
remodeling, which was greater in those with more
severe mitral regurgitation. Moreover, those allo-
cated to treatment had signiﬁcant improvements
compared with their baseline measurements in all
clinical outcomes at 12 months.
As a proof-of-concept study, the REDUCE-FMR
trial was not powered to show between-group dif-
ferences in the pre-speciﬁed exploratory patient-
oriented clinical endpoints of NYHA functional
class, 6-min walk test distance, and quality of life.
Furthermore, blinding of patients reduces the pla-
cebo effect associated with treatment and reduces
the nocebo effect in the control group (19), although
also potentially having an impact on the Hawthorne
effect on the control group (20). Accordingly, in the
REDUCE-FMR trial, patients allocated to the control
group also experienced trends toward an improved
quality of life and an increase in 6-min walk test
distance, despite a deterioration in their hemody-
namic data. Thus, although there were attenuations
of the clinical improvements compared to prior
nonblinded studies (6–8), despite blinding, the
treatment group in REDUCE-FMR experienced ben-
eﬁts in multiple clinical variables compared with
baseline.
FIGURE 5 NYHA Functional Classiﬁcation Change at 12 Months
NYHA functional class at baseline and 12 months comparing the treatment and control
groups. At 12 months, the distribution of NYHA functional class altered favorably in the
treatment group (p ¼ 0.002 for change) and stayed constant in the control group
(p ¼ 0.75). NYHA ¼ New York Heart Association.
TABLE 3 Key Safety Outcomes During 12-Month Follow-up According to ITT Analysis
Total
(N ¼ 120)
Control
(n ¼ 33)
Treatment
(n ¼ 87)
Cumulative major adverse events 16.7 (10.5–24.6) 18.2 (7.0–35.5) 16.1 (9.1–25.5)
Deaths 13.3 (7.8–20.7) 15.2 (5.1–31.9) 12.6 (6.5–21.5)
Myocardial infarction 3.3 (0.9–8.3) 3.0 (0.1–15.8) 3.4 (0.7–9.7)
Cardiac perforation 0.0 (0.0–3.0) 0.0 (0.0–10.6) 0.0 (0.0–4.2)
Device embolism 0.0 (0.0–3.0) 0.0 (0.0–10.6) 0.0 (0.0–4.2)
Surgery or PCI related to device 0.0 (0.0–3.0) 0.0 (0.0–10.6) 0.0 (0.0–4.2)
Post-procedure interventions
Post-procedural CRT implantation 4.2 (1.4–9.5) 6.1* (0.7–20.2) 3.4 (0.7–9.7)
Exit for percutaneous mitral valve
repair, surgery, LVAD, CRT or heart
transplantation
5.8 (2.4–11.7) 12.1† (3.4–28.2) 3.4‡ (0.7–9.7)
Heart failure hospitalization 30.0 (22.0–39.0) 36.4 (20.4–54.9) 27.6 (18.5–38.2)
Values are % (95% conﬁdence interval). There were no signiﬁcant between-group differences. *1 patient
withdrew from CRT implantation. All other subjects who underwent CRT implantation remained in the study.
†1 additional subject completed the ﬁnal follow-up visit after placement on heart transplant list. ‡2 of the 3
treatment patients who exited the study for alternative therapies did not receive an implant.
CRT ¼ cardiac resynchronization therapy; LVAD ¼ left ventricular assist device; PCI ¼ percutaneous coronary
intervention; other abbreviations as in Table 1.
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953Another percutaneous mitral intervention for FMR,
the MitraClip (Abbott Laboratories, Rockville, Mary-
land), has recently been assessed in 2 unblinded
randomized trials, with discordant results (5,21). Lack
of treatment blinding, patient selection strategies,
and imbalances in medical management between the
intervention and standard of care arms of these trials
may have contributed to the dramatically different
results seen in the 2 MitraClip trials.
Additional novel features of REDUCE-FMR were
the use of quantitative echo parameters as the pri-
mary endpoint for the study and the inclusion of
patients with mitral regurgitation grade 2þ. This is in
contrast to the MitraClip studies COAPT (Cardiovas-
cular Outcomes Assessment of the MitraClip Percu-
taneous Therapy for Heart Failure Patients with
Functional Mitral Regurgitation) (5) and MITRA-FR
(Multicentre Study of Percutaneous Mitral Valve
Repair MitraClip Device in Patients With Severe Sec-
ondary Mitral Regurgitation) (21), which only enrolled
patients with 3þ and 4þ mitral regurgitation. Enroll-
ment in the current trial was determined by investi-
gator assessment of baseline images at the time of the
procedure, but formal echo analyses were later done
by a core echocardiography laboratory. There were
several discrepancies between the site and core lab-
oratory assessment of FMR severity at baseline, with
approximately 30% of enrolled patients having mitral
regurgitation grades <2þ on core laboratory assess-
ment. Examination of transmitted images suggests
that the poor correlation between the color jet area
and more robust quantitative measurements may be
partially responsible (12). Although this phenomenon
was matched across the 2 arms, the enrollment of a
patient population with a lesser degree of mitral
regurgitation would, if anything, make it more difﬁ-
cult to demonstrate any improvement in the primary
endpoint in those allocated to treatment. However,
treating mitral regurgitation early might be associ-
ated with better longer-term results than waiting
until LV remodeling has progressed, by which time
the degree of the mitral regurgitation loses its effect
on prognosis (22).
Moreover, there were fewer paired echocardiogram
scans that were suitable for quantitative assessment
than expected; for example, only 39% of control pa-
tients had paired interpretable cardiac ultrasonogra-
phy scans at 1 year, considerably lower than patients
assigned to treatment (62%). This was in part due to a
higher dropout rate among control patients to un-
dergo alternative therapies. Acquisition of echocar-
diograms of sufﬁcient quality has also been a
limitation in other studies in this ﬁeld. Adequate
imaging for quantitative assessment of FMR wasavailable in 57% of COAPT and 43% of patients with
MITRA-FR (5,21).
Finally, most procedures were performed in in-
stitutions without prior experience with the Carillon
mitral contour system. Physician proctors were
present for initial cases, but all early system results
are included in the data presented. Importantly,
the device was suitable for most patients, with only
a small portion (8 of 87) of patients who had
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: FMR
is a common ﬁnding in patients with HFrEF and is
associated with a poor prognosis. Transcatheter mitral
valve repair is a rapidly emerging ﬁeld. An indirect
annuloplasty device, accessed through the jugular
vein can reduce regurgitant volume.
TRANSLATIONAL OUTLOOK: Randomized,
double-blind, controlled studies can be completed
safely in interventional cardiology and should be the
ambition for future studies in this ﬁeld. More data are
needed to determine if reducing FMR in patients with
HFrEF improves quality of life and hospitalization and
survival rates.
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954the device was not anatomically suitable for
implantation.
In spite of these challenges, use of the Carillon
mitral contour system was associated with a statisti-
cally signiﬁcant reduction in mitral regurgitant
volume and in LV volumes at 1 year compared to
a blinded, sham-controlled population, on an
intention-to-treat analysis. Because beneﬁcial LV
remodeling is consistently associated with mortality
beneﬁt (23), these data suggest that the Carillon de-
vice may be associated with important clinical bene-
ﬁts; this will need to be assessed in future trials.
STUDY LIMITATIONS. As previously outlined, not all
patients had echocardiogram scans of sufﬁcient
quality for mitral regurgitation quantiﬁcation, and LV
volumes assessment and fewer patients with
moderate-severe FMR at baseline were enrolled than
planned or anticipated. Despite these limitations, the
study achieved its primary endpoint. REDUCE-FMR
was not powered to evaluate clinical endpoints.
Finally, duration of follow-up was limited to 1 year.
Therefore, long-term effectiveness and safety of the
device is unknown, although for patients with HFrEF
and mitral regurgitation, 1 year is a signiﬁcant pro-
portion of their remaining life expectancy. The
currently enrolling, blinded, sham-controlled
CARILLON trial has been powered to assess the
impact of the Carillon indirect mitral annuloplasty
device on mortality and hospitalization in patients
with FMR with 5 years of follow-up.
CONCLUSIONS
In this ﬁrst blinded and sham-controlled randomized
controlled trial of a percutaneous heart valve therapy,
REDUCE-FMR has demonstrated that a low-risk
transvenous approach to mitral annuloplasty can
successfully and safely reduce FMR. This reduction
is associated with reverse LV remodeling. The
simplicity of this approach is supported by the study
being largely done by centers previously unfamiliar
with the technology. Other advantages include theright-sided approach, avoidance of trans-septal
puncture, and the fact that Carillon device place-
ment does not preclude any future mitral valve
treatment if needed later. Studies are now underway
to assess the effect of this approach on clinical
outcomes.
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